Skip to main content

Advertisement

Table 3 Relationship of circulating unadjusted geometric mean concentrations of IGF-I and IGFP-1–7 (ng/mL) with select participant characteristics in postmenopausal women

From: Relationship of circulating insulin-like growth factor-I and binding proteins 1–7 with mammographic density among women undergoing image-guided diagnostic breast biopsy

Characteristics N IGF-I IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 IGFBP-7
Mean1 (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
 Age at biopsy (years)
  <55 30 105 (94–116) 0.66 (0.09–1.23) 335 (271–398) 3563 (3248–3878) 150 (135–165) 388 (357–420) 184 (166–201) 113 (106–121)
  55–59 38 111 (101–121) 0.40 (0.09–0.72) 333 (275–392) 3578 (3370–3787) 159 (145–172) 416 (384–447) 164 (150–177) 115 (110–121)
  ≥ 60 35 92 (81–103) 0.94 (0.42–1.63) 333 (278–388) 3340 (3027–3652) 159 (147–170) 377 (348–405) 181 (168–194) 121 (114–128)
  p trend (p het)   0.67 (0.03) 0.51 (0.32) 0.97 (0.99) 0.26 (0.40) 0.38 (0.61) 0.54 (0.18) 0.87 (0.10) 0.08 (0.20)
 Education
  ≤ High school grad/GED 22 108 (93–124) 3.13 (1.88-4.37) 287 (221–353) 3694 (3383–4005) 167 (147–186) 398 (356–440) 173 (155–192) 119 (107–131)
  Some college/tech school 19 105 (93–118) 2.79 (1.81-3.78) 314 (252–375) 3389 (3031–3748) 151 (136–166) 415 (379–451) 191 (165–216) 116 (107–126)
  ≥ College graduate 62 100 (92–108) 3.42 (2.68-4.15) 359 (311–406) 3453 (3236–3670) 154 (145–164) 386 (363–409) 171 (162–181) 116 (113–120)
  p trend (p het)   0.31 (0.59) 0.56 (0.67) 0.07 (0.20) 0.33 (0.44) 0.29 (0.39) 0.46 (0.50) 0.58 (0.25) 0.65 (0.88)
 Body mass index (kg/m2)
  < 25 41 104 (95–112) 1.62 (0.61–2.63) 446 (397–494) 3343 (3154–3532) 141 (130–153) 396 (371–421) 166 (154–177) 114 (110–119)
  25.0–29.9 31 103 (91–114) 0.83 (0.20–1.47) 323 (263–383) 3631 (3328–3934) 168 (153–182) 388 (354–423) 179 (164–193) 112 (106–118)
  ≥ 30 31 101 (87–115) 0.13 (0.03–0.23) 235 (194–276) 3554 (3183–3926) 166 (155–177) 398 (362–433) 185 (166–203) 125 (117–133)
  p trend (p het)   0.78 (0.96) < 0.0001 (< .0001) < 0.0001 (< .0001) 0.25 (0.30) 0.005 (0.004) 0.95 (0.92) 0.06 (0.16) 0.03 (0.02)
 Age at menarche (years)
  ≤ 12 42 105 (97–112) 0.44 (0.11–0.76) 317 (262–371) 3587 (3352–3821) 157 (146–168) 389 (363–416) 180 (166–194) 114 (109–119)
  13 34 99 (86–111) 0.89 (0.17–1.61) 374 (311–436) 3365 (3055–3675) 149 (136–161) 392 (360–423) 176 (164–188) 120 (114–126)
  ≥ 14 26 109 (96–122) 0.63 (0.09–1.17) 315 (256–374) 3558 (3259–3858) 163 (144–181) 409 (371–447) 166 (147–184) 117 (108–126)
  p trend (p het)   0.72 (0.46) 0.45 (0.44) 0.87 (0.32) 0.76 (0.48) 0.71 (0.38) 0.43 (0.68) 0.19 (0.41) 0.40 (0.44)
 Age at first birth (years)
  Nulliparous/ ≥ 30 years 37 108 (98–118) 0.54 (0.11–0.97) 359 (300–418) 3588 (3351–3825) 151 (137–165) 388 (357–419) 178 (163–193) 116 (111–122)
  < 30 years 66 100 (92–108) 0.67 (0.29–1.05) 320 (279–361) 3438 (3225–3650) 159 (150–168) 397 (376–419) 174 (163–184) 117 (112–122)
  p het   0.24 0.64 0.29 0.39 0.30 0.63 0.64 0.82
 Parity
  Nulliparous (0) 22 103 (89–116) 0.43 (− 0.02–0.89) 326 (253–398) 3542 (3197–3888) 160 (140–180) 365 (334–395) 187 (167–208) 118 (110–125)
  1 20 105 (90–119) 0.71 (− 0.09–1.52) 326 (244–408) 3468 (3151–3785) 152 (135–168) 417 (375–458) 171 (151–192) 113 (107–119)
  2 42 99 (88–110) 0.76 (0.24–1.29) 338 (288–389) 3445 (3150–3739) 163 (153–173) 393 (366–420) 179 (168–190) 121 (114–128)
  ≥ 3 19 110 (99–120) 0.51 (−0.05–1.06) 341 (255–428) 3559 (3278–3841) 142 (125–160) 408 (356–460) 158 (138–178) 111 (104–118)
  p trend (p het)   0.78 (0.71) 0.72 (0.80) 0.72 (0.99) 0.95 (0.95) 0.40 (0.23) 0.23 (0.27) 0.09 (0.15) 0.71 (0.17)
Characteristics N IGF-I IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 IGFBP-7
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
 Oral contraceptive use
  Never 15 90 (77–103) 1.14 (−0.04–2.32) 291 (230–352) 3214 (2799–3630) 164 (138–190) 414 (374–454) 175 (151–199) 117 (109–126)
  Former 88 105 (98–112) 0.56 (0.27–0.84) 342 (303–380) 3540 (3367–3714) 155 (147–163) 391 (371–410) 175 (166–184) 117 (113–121)
  p het   0.08 0.29 0.28 0.15 0.41 0.38 0.99 0.89
 Menopausal hormone use
  Never 67 101 (93–110) 0.65 (0.28–1.01) 329 (287–372) 3464 (3270–3659) 159 (149–168) 392 (371–413) 174 (164–184) 116 (111–121)
  Former 36 105 (96–115) 0.57 (0.11–1.03) 342 (287–398) 3541 (3252–3830) 152 (139–165) 398 (365–431) 177 (161–193) 118 (113–124)
  p het   0.55 0.81 0.72 0.66 0.40 0.75 0.79 0.60
 Family history of breast cancer in a first-degree relative
  None 75 103 (97–110) 0.53 (0.24–0.83) 333 (295–371) 3490 (3321–3660) 155 (146–164) 391 (371–412) 172 (162–182) 117 (112–121)
  1 or more 27 102 (86–118) 0.90 (0.13–1.67) 344 (270–418) 3469 (3073–3865) 160 (145–174) 404 (366–441) 184 (167–200) 117 (111–123)
  p het   0.83 0.33 0.78 0.91 0.59 0.55 0.26 0.88
 Age at menopause
  < 45 17 95 (77–113) 0.91 (− 0.01–1.84) 287 (208–367) 3389 (2996–3783) 168 (143–193) 411 (378–444) 181 (158–203) 118 (111–126)
  45–49 26 114 (103–126) 0.40 (0.02–0.79) 305 (245–365) 3585 (3257–3913) 153 (140–166) 415 (377–453) 164 (148–180) 119 (109–130)
  ≥ 50 48 105 (97–112) 0.57 (0.18–0.96) 351 (300–402) 3607 (3411–3803) 153 (142–165) 380 (353–407) 180 (168–193) 115 (111–120)
  p trend (p het)   0.53 (0.11) 0.67 (0.54) 0.14 (0.32) 0.36 (0.58) 0.28 (0.42) 0.14 (0.23) 0.70 (0.28) 0.48 (0.69)
 Cigarette smoking
  Never 37 103 (91–116) 0.68 (0.16–1.21) 357 (296–418) 3491 (3144–3838) 157 (145–168) 387 (358–416) 184 (168–201) 119 (113–124)
  Former 47 105 (97–114) 0.40 (0.12–0.68) 296 (250–342) 3546 (3371–3722) 155 (144–167) 418 (391–444) 174 (164–184) 117 (112–122)
  Current 11 89 (71–108) 2.60 (−0.06–5.25) 382 (297–466) 3167 (2789–3544) 178 (151–204) 355 (307–402) 149 (125–173) 113 (93–133)
  p trend (p het)   0.39 (0.31) 0.45 (0.06) 0.66 (0.16) 0.45 (0.36) 0.29 (0.25) 0.87 (0.07) 0.02 (0.04) 0.43 (0.70)
 Breast biopsy prior to enrollment
  Never 62 102 (94–109) 0.67 (0.26–1.08) 344 (300–387) 3429 (3251–3607) 158 (148–168) 404 (384–425) 175 (163–186) 115 (112–119)
  Ever 39 105 (93–117) 0.50 (0.13–0.87) 313 (258–369) 3610 (3287–3933) 156 (144–167) 379 (346–412) 177 (163–190) 119 (112–127)
  p het   0.66 0.55 0.39 0.30 0.76 0.18 0.84 0.32
 Biopsy diagnosis
  Benign non-proliferative 31 103 (93–113) 0.94 (0.19–1.68) 369 (313–426) 3556 (3282–3830) 152 (137–166) 409 (379–439) 169 (152–186) 114 (107–121)
  Proliferative with/without atypia 47 103 (92–114) 0.47 (0.13–0.80) 307 (257–356) 3499 (3237–3760) 163 (151–175) 381 (353–409) 180 (168–192) 121 (115–127)
  In-situ/invasive 25 103 (91–114 s) 0.63 (0.05–1.21) 345 (271–418) 3397 (3097–3698) 149 (136–162) 401 (368–433) 175 (159–191) 112 (107–117)
  p trend (p het)   0.95 (0.99) 0.49 (0.46) 0.55 (0.29) 0.49 (0.78) 0.87 (0.28) 0.67 (0.39) 0.57 (0.56) 0.75 (0.12)
  1. CI confidence interval, IGF insulin-like growth factor, IGFBP IGF binding protein
  2. 1IGF-measures were log-transformed
  3. p values < 0.05 are in italics